Related Experiment Video
Updated: Dec 13, 2025
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease
Yan-Fang Xian1,2, Chang Qu1, Yue Liu3
1School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China.
Abstract:
Alzheimer's disease (AD) is a common neurodegenerative disease characterized by progressive memory loss. Magnolol (MN), the main active ingredient of Magnolia officinalis, possesses anti-AD effects in several experimental models of AD. In this study, we aimed to explore whether MN could ameliorate the cognitive deficits in TgCRND8 transgenic mice and to elucidate its molecular mechanisms. Male TgCRND8 mice were orally administered with MN (20 and 40 mg/kg) daily for 4 consecutive months, followed by assessing the spatial learning and memory functions using the open-field, radial arm maze, and novel object recognition tests. The results demonstrated that MN (20 and 40 mg/kg) could markedly ameliorate the cognitive deficits in TgCRND8 mice. In addition, MN significantly increased the expression of postsynaptic density protein 93 (PSD93), PSD-95, synapsin-1, synaptotagmin-1, synaptophysin (SYN), and interleukin-10 (IL-10), while markedly reduced the protein levels of tumor necrosis factor alpha (TNF-α), IL-6, IL-1β, Aβ 40, and Aβ 42, and modulated the amyloid precursor protein (APP) processing and phosphorylation. Immunofluorescence showed that MN significantly suppressed the activation of microglia (Iba-1) and astrocytes (GFAP) in the hippocampus and cerebral cortex of TgCRND8 mice. Mechanistic studies revealed that MN could significantly increase the ratios of p-GSK-3β (Ser9)/GSK-3β, p-Akt (Ser473)/Akt, and p-NF-κB p65/NF-κB p65. These findings indicate that MN exerted cognitive deficits improving effects via suppressing neuroinflammation, amyloid pathology, and synaptic dysfunction through regulating the PI3K/Akt/GSK-3β and NF-κB pathways, suggesting that MN is a promising naturally occurring polyphenol worthy of further developing into a therapeutic agent for AD treatment.
Insights
Magnolol (MN) significantly improved cognitive deficits in Alzheimer's disease (AD) mouse models. This natural compound reduced neuroinflammation, amyloid pathology, and synaptic dysfunction, suggesting its therapeutic potential for AD.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss.
- Magnolol (MN), a key component of Magnolia officinalis, has demonstrated potential anti-AD effects in experimental settings.
Purpose of the Study:
- To investigate the efficacy of Magnolol (MN) in ameliorating cognitive impairments in TgCRND8 transgenic mice, a model for Alzheimer's disease.
- To elucidate the underlying molecular mechanisms by which MN exerts its neuroprotective effects.
Main Methods:
- TgCRND8 mice were orally administered MN (20 and 40 mg/kg) daily for four months.
- Cognitive functions were assessed using behavioral tests: open-field, radial arm maze, and novel object recognition.
- Molecular analyses included Western blotting for synaptic proteins, inflammatory markers, amyloid-beta (Aβ), and signaling pathway components (PI3K/Akt/GSK-3β, NF-κB); immunofluorescence was used to assess microglial and astrocyte activation.
Main Results:
- MN treatment significantly improved spatial learning and memory in TgCRND8 mice.
- MN administration reduced levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and Aβ peptides (Aβ40, Aβ42), while increasing levels of synaptic proteins (PSD93, PSD-95, synapsin-1, synaptotagmin-1, SYN) and IL-10.
- MN suppressed microglial (Iba-1) and astrocyte (GFAP) activation and modulated APP processing and phosphorylation, alongside increasing p-GSK-3β/GSK-3β, p-Akt/Akt, and p-NF-κB p65/NF-κB p65 ratios.
Conclusions:
- Magnolol (MN) effectively ameliorates cognitive deficits in a mouse model of Alzheimer's disease.
- MN exerts its beneficial effects by suppressing neuroinflammation, reducing amyloid pathology, and improving synaptic function.
- The mechanisms involve the regulation of PI3K/Akt/GSK-3β and NF-κB signaling pathways, highlighting MN as a promising therapeutic candidate for AD.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...